Deanne Randolph | Investor Relations |
Frank Bedu-Addo | Chief Executive Officer |
Lauren Wood | Chief Medical Officer |
Michael King | Interim Chief Financial Officer |
Greetings, and welcome to PDS Biotechnology's Second Quarter 2020 Financial Results. At this time all, participants are in a listen-only mode. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Deanne Randolph, Investor Relations.
Good morning, and welcome to PDS Biotechnology's second quarter 2020 earnings conference call and audio webcast. Dr. are today me With Frank Bedu-Addo, Dr. Executive Officer; Chief Lauren Chief Financial Medical Officer; King, Interim and Michael Officer. Wood, Chief Earlier this XX, morning, financial PDS Biotech issued a the months results press three ended June XXXX. for release announcing read today's report the quarterly XX-Q, SEC We encourage afternoon. Form everyone press as PDS on filed well be will release, which this Biotech's as with to posted The the quarterly and Company's at website pdsbiotech.com, release press will is later be Biotech's available on PDS today. report
and webcast In archived will addition, website conference the this be being for through reference. is future there Company's call
we to involve Reform Safe Before the the caution that of Act risks comments of forward-looking begin, material will statements meaning materially. forward-looking and uncertainties, and Litigation including call laws, Harbor actual during XXXX. These management provisions the listeners federal I would securities Company's the within of like made the results differ statements conference include Securities by may Private
morning's factors, to on such others, operations, discussion among the related ability a including and Company's the business related the pandemic of a and operations, those to financial Company's risks results For challenges, the respond operations, impact of this may the refer Biotech's to filings. COVID-XX, listeners and such statements. including have are to potential place reliance release, in to SEC undue carefully other press consider on are forward-looking investors, the PDS and these to forward-looking statements, noted Investors. urged factors this evaluating please in cautioned not
reflect call public now the I advised Company place that circumstances broadcast, Frank of contains the turn not XX, undertakes we like will the the of or Please revise call the accurate the announced call this take prospectus for time-sensitive With taking content required of offering, Frank? since as the Dr. that, the refer would over call. date that statement information. after update previously conference it's any further conclusion the Please questions we to obligation by of XXXX. at this today. date to to August that of be addition, in a live to or information middle are of events be to In no only Except the law, is Bedu-Addo.
clinical XXXX last quarter's Thank call, to we trial This environment progress our COVID-XX you, PDSXXXX. disease planning On immuno-oncology challenging that we X and call. second quarter, past looking across of quarter program, development Deanne, and operations, reported programs, significant conference Phase we despite made both PDS earnings Biotech's due for the to everyone, to our forward lead pandemic. welcome, global and initiating were clinical earnings infectious the
our universal development intention disease We also to both the programs announced to influenza. COVID-XX for vaccines and infectious broaden our of include
report. quickly me has Let the our since that been made summarize progress last
fund Farmacore, pre-clinical the various from some of planned you initiated clinical first This product, advanced advanced to three the our the with treatment weeks. and to focused programs. we received of and the will a X second in PDSXXXX, to A Brazilian various from the I'll initiated been recruiting localized our clinical vaccines. has We advanced development Cancer been to planned on cancers, with PDSXXXX has studies of Promising immune-based few COVID-XX currently generated, pre-clinical company, second with at three a mentioned, schedule. announced MD FDA initiated. X Phase in trial funding pre-clinical Brazil's on partnership PDSXXXX ongoing lead regarding according Ministry The oncology HPV-associated Science, of June as Phase provide of study pleased Innovation was cervical and have Phase been initiate the first In in and is collaboration in activities. our X now our cancer our clinical it's to Anderson detail of start perform I data portfolio, NIAID oncology the discussions with diverse in our HPV-associated award flu An data COVID-XX be were package also cancers. the is Communication. with universal Center. of developed trial vaccine from due vaccine granted next Technology, strategy I of being
animal is may of an National at PDSXXXX Some the pre-clinical of to were an in design fact pre-clinical studies Phase Immunotherapy recently owned EMD of and tumor a triple immune-therapeutic Cancer. this that synergy the in with is Journal a three initiation you of by The Institute, anti-cancer which demonstrated NHS-ILXX, the NCI enhanced checkpoint agents leading novel independent the studies stage targeted results published X result MXXXX, this combining These clinical performed inhibitor, be cytokine. trial the agents, was study models. efficacy Serono, strong two between for aware the of combination of bifunctional which Cancer
basis of Ann oncology. standard combination a the MD, Professor which who of will PDSXXXX this is a the underway, this are provide at The radiation is additional to we Texas outcomes Associate investigate X details H. PhD, Dr. investigator, of of that University We to the care, correlation June the study and second over the On X the safety with advanced X the announced study. on also believe study pleased clinical of we performed as in tumors. Wood have therapy. collaboration Phase of trial with evaluate Anderson lead Cancer study Dr. patients Clark, chemoradiotherapy. this combination MD demonstrate platform Phase enhanced being of to cancer potential This that And with to will clinical therapeutic potential strong multiple biomarkers this in treatment aggression cancer has safety PDSXXXX different chemoradiation PDSXXXX clinical patients immune a to and clinical Houston. to will is Center benefit immunotherapeutic X, a advanced locally believe Phase clinical be conducted cervical in NCI-led solid tumor triple locally applicable with form We response of combination trial has the care novel of cervical of cancer. with this standard specific
Phase mentioned any April On currently which of in We is XX, I three initiated we expect earlier, as announced PDSXXXX events. second few the planned the to that unforeseen trials, the weeks, be next the study, barring initiation Keytruda, of delayed pandemic impact combination been care to COVID-XX cancer had and operations. X severe the PDSXXXX of of due the the trial XXX VERSATILE on adverse evaluating trial, the standard multi-site of
will We This possibility PDSXXXX have future. and currently trial VERSATILE the remained in Phase trial, the sites, in reopening contact the X when with XXX trial. our evaluating the third clinical close we near are initiated, be clinical of
or among note Now, immunotherapeutic in addresses of cancer. that it to studies, formulation this line treatments metastatic that the is XXX important unique quite recurrent trial immuno-oncology is VERSATILE first
efficacy of addition As preliminary been a PDSXXXX currently means take with and with of potential cancer chemotherapy. with equally Each these immunotherapeutic this the strong to to clinical has without planned agents, three Phase therapeutic PDSXXXX oncology may forward clinical reporting and of will high-quality PDSXXXX that to world Keytruda has forward initiating will as trials feasible. the strategy novel patients we reasonably we as of previously the believe improved noticed, the efficacy promising opportunity renowned in immunotherapy combining first our have the comprehensive you first PDSXXXX leader care treatment, study in look the PDSXXXX future. of these partnered patients. X treatment lead other outcomes been options line of to to on providing as PDS look the enhance in these a We the soon to of of has the line with this disease, one goal Phase the standard the or having of treated have and progressing and Each Keytruda Biotech, field. and combinations, X combinations provide of implemented trials
tumor in the the into initially resistance agreement. a and we novel of tumor with activate cancers, collaboration cooperative research combines often the the MUCX the tumor Now, under its of an to These expressed our including expressing lung associated T-cells the with immunotherapy. clinical and National and strongly the and tumor other the moving by on These protein with presence broader evaluate Institute the to or present include with Institute multiple to recognize of attack and oncology as immunotherapeutic announced progression will expansion MUCX the the proprietary combination cells. trained development and be clinical our known agreement is human or Mucin immune potential Cancer existing poor colorectal, to T-cells, types, peptides from pre-clinical and the collaboration the agents studies, drug Versamune expanded more National from platform proteins PDSXXXX kill train PDSXXXX Earlier PDSXXXX Cancer prognosis. this novel native recognized is National to peptides disease this PDSXXXX studies highly MUCX X is MUCX. small preclinical trial Under pipeline. by were Cancer year, ovarian, developed associated modified sequences sequences in breast, Institute. system. in their human are designed MUCX peptide in PDSXXXX to agreement, with
partnering Our Versamune-based towards comprehensive our field strategy several proof has and oncology leading in efficacy experts expand cancer us with the to indications. in the of opportunity some of provided of with the immunotherapy progress of cancer efficiently concept pipeline
immuno-oncology our infectious addition in portfolio. to with made disease progress mentioned progress I pipeline, also As made our the earlier, with significant we've
influenza, partnering We to of have and pipeline expert robust tuberculosis, Versamune-based approach similar preventive for taken a very develop efficiently with institutions a vaccines COVID-XX.
between year, in Biotech results. announced we Initial amended recall, testing the PDS Farmacore, and develop Brazilian this As collaboration and vaccine to vaccine promising you a may an February demonstrated company, development has of tuberculosis. for Versamune-based pre-clinical research
with Biotech disease would conducted vaccine. the testing development that Biotech, announced continues at In TB Farmacore. Formulation be our to further we be April, animal PDS pipeline PDS beyond expanding pre-clinical by infectious
demonstrated of added COVID-XX three active the what of antibody our last focus on importance of refer our order addition data the of the CDX within next highlighted inducing our which to PDSXXXX rapid T-cell responses review technology Lauren the both Dr. platform with pipeline, fact in occurred COVID-XX and to momentarily. four we are out The of just applying promising which for agencies have and of immunity we development potentially Over protection PDSXXXX T-cells, global to immune two of antibodies, more COVID-XX Wood vaccine. feedback high the us emerging disease preliminary neutralizing developing as levels T-cells vaccine to recently the addition of clinical against in candidate, data discussions induction XX reported killer inducing has Of development allowed neutralizing days role of vaccination. to the to initiate will partnered. CDX development in that We to current the in pre-clinical the and receive recently this from of virus-specific data three antibodies. the durable infectious T-cells, regulatory regarding pandemic achieve infection. PDSXXXX, pre-clinical results vaccines Versamune is pre-clinical COVID-XX generating for COVID-XX strong detail we plan. more are note These Despite on helper in important vaccines, capable the T-cells vaccines generation months,
of continue Versamune a COVID-XX Technology, by Brazil, this Brazil's rapidly safe, second and our potentially the the antibody provides engaged vaccine strains the PDSXXXX continuing switch provided combining influenza spread assess the to scientific discussions funding the regarding June, and longer our will a continue testing the organizations Institute we of Versamune We In University and and COVID-XX Versamune PDSXXXX award discussions quickly next validation to T-cell us human to and clinical multiple with NIAID, future PDSXXXX, look Ministry flu our promise resources development as provide recombinant candidate, of of expansion Phase other a Medicine, partnerships. to pre-clinical advanced X and Communication. development Allergy development be disease Innovation, novel look Infectious We of strains of announced activating our also vaccine of the from simple, infectious to a In in inducing We advance pre-clinical grant forward induces COVID Kentucky disease School with generation Professor its governments We collaboration strategy clinical Phase work at of accelerate development PDS Farmacore of are Biotech infections. announced This believe National allow collaboration the newly platform June, a towards protein. now applying of influenza. Woodward, expanded PDS through and we forward accelerate in non-government our Farmacore-developed effective of will oncology durable, against with development T-cell to collaborator vaccine. the advancing platform of T-cell Under both the to toward trials. at NIAID, awarded agreement, believe development with We University the with pipelines working until that support government against Jerold responses and Science, to adverse SARS-CoV-X the development to COVID-XX flu. continuing of immune-based to further multiple Farmacore recently and efficacy was commercialization. reduce Kentucky I initial provide these portfolio, that strategically to us virus. with protective, recent and Diseases, our of our that clinical the grants with lasting of a of universal X and financial infectious by both collaborations enhances to broadly vaccine and
of that financing. financial Most $XX.X know you may Company Moving million our on to a position. completed the just
Michael robust optimize and uncertainties market vaccines volatility our the of have resources. factors, ability and a Biotechnology's data would Chief our the additional oncology experts Lauren considering of partnering clinical through necessary over raise Lauren? disease to and currently COVID-XX limit us value by data important extremely X provided focus is this the updates all Barring on with financial to I It interim use Company financial provide proof recent concept. any will on advance Officer, Company or generation. provides created the PDS with the discuss with of and trials initial and in resources the Phase build now the by position. strategy financial of Company This infectious Company's products Dr. to call clinical to unusual and the the with to is Our us product unique like to quite the the to information to therapies development, cancer financial other disease and for generation infectious providing events, resources especially to King, our CFO, runway. hand PDSXXXX some financial allows important, Company's to the our these pipelines. three and with to of efficiency of advance planned Wood, Medical has pipeline the portfolio unforeseen opportunity the clinical
Thank again, everyone, conference you, and to call. once this Frank, welcome, morning's
a our our The in progress both X As few the study of we months with National opening the in made Frank immuno-oncology remarks, past our pipelines. Institute over lead initiation infectious clinical mentioned demonstrate of influenza, have significant recent Phase and products his disease on continued in for Cancer repository data commitment pre-clinical clinical commercialization. progressing platform, our COVID-XX and successful PDSXXXX, well as our candidate, as our work Versamune scientific and through to continue while to building to strong the clinical development
I our clinical I'd technology Versamune platform works. to Before overview like advancements, a provide quick the how review recent of
as broad of killer develop of many of and to for T-cells these while importance is generation an the delivers Likewise, generating therapeutic to to arm recognition system activating of processing, turn both virus T-cells. recent present kill on in responses immune by system. opportunity ability proteins to pipeline ability activities for multiple rapidly or for human result immune attacking neutralizing to with Type to long-term combining or PDXXXX. immunologic infectious Versamune vaccines as the Versamune prophylactic in treatments the disease by these ability current T-cell simultaneously also immune approaches that proteins uptake both Activated and from in product have Versamune's the disease-specific preventative protection antibodies. infected cells, interferon critical memory. potent proprietary effectively candidate, generating T-cells associated the system Our pathway. Versamune important these as key both and disease, well I'll activated provide X rapidly initiations well oncology tumor our critical pathogens. We and virus the immune are that our and demonstrated activate technology and a disease-specific disease-specific neutralizing disease antibodies include as these potent overcomes to improve to provides infectious enhance lead called the immune our the near-term new killer antigens identify effective believe T-cells and generate two activating limitations The to of and antibodies important outcomes. as study cancer These cells, defensive immuno-oncology killer T-cells, powerful based now
novel a As short associated had HPV from human with papillomavirus with of that and conjugated this proteins, a remember, enroll we of related Phase and PDSXXXX patient response of pleased combination This mix MXXXX Institute with anal, rate type cervical, X of will patients called cancer. primary very other evaluate dosed approximately NHS-ILXX. study to head were in modulating in most first inhibitor, immune antibody the HPV-associated in is a its neck, clinical of may Cancer checkpoint two combination and the PDSXXXX study Versamune an the combination the high-risk cancer, agents, is the you virulent cytokine of proprietary National endpoint the announce HPV development XX, with bifunctional and novel advanced triple objective cancers. June, XX In and to
look will trial CDX patients patients clinical induce in killer improve outcomes to next the critical response We of ability The clinical on safety combination the this published to combination, and updates significantly based believe that HPV-associated as this potential Versamune's for study, with evaluated progresses. of T-cells, for first to validating the pre-clinical forward metastatic a data enrollment. this recurrent be before has trial to eight step the objective represents and triple cancers. levels We full providing high expands tumor-specific
important to trial, and evaluate for standard second Biotech advanced XX combination preparing investigate immune chemoradiotherapy Anderson and localized of of MD Center strong response. approximately Cancer are therapy ability This conducted to cervical with patients to that PDSXXXX's in PDSXXXX PDS biomarkers various the cancer. potential trial patients, PDSXXXX T-cells demonstrated to improve in of provides chemoradiation be treatments activate We cancer. cervical with safety combination earlier, will system treatment combinations tumor-retargeting care a mentioned the and its correlation of the immune believe anti-tumor with induce killer Frank As activity preliminary to to initiate to
the regarding have clinical early implemented sites Sites as in been ensure PDSXXXX ongoing as paused with well VERSATILE clinical of research Finally, the to pandemic. despite have that Keytruda of was patients we of frequent measures COVID-XX. months study safety with staff, our in the our communication conduct and XXX studies, institution-specific combination of the in
will receive combination patients study, administered the Keytruda three of progression. cycles On total context of until care therapy, standard every in of the five therapy a of weeks disease
patients' many paused, enhance studies options reactivate Although disease year to did novel not. treatments treatment this study able PDSXXXX's end, care being oncology to were recurrent about the with of clinical needs cancers. advanced by for for and remain optimistic for to confirming contribution ability cancer study's patients We metastatic anticipate standard
SARS-CoV-X CDX helper CDX to rapid as as capable T-cells, in induction infection. Now, achieve announced which would neutralizing next This In in of T-cells durable in summarize the like neutralizing platform more virus-specific against generation data I COVID-XX studies, our potent our recently with recombinant demonstrated from to highlighted killer a vaccine. pre-clinical antibodies high SARS-CoV-X, pre-clinical CDX to levels highly emerging research T-cells, the that of virus play potentially that well that our Versamune development as of developing are and of for antibody derived Recent PDSXXXX induce vaccines and protein T-cells. knowledge antibodies. highlights We has role response, CDX COVID-XX. CDX a causes providing the COVID-XX. sections of as protection important COVID-XX recognized CDX includes virus-specific may by protein importance well work addition that against sections PDSXXXX, an pairs generating The protection
are also studies memory virus-specific protection. for which of pre-clinical long-lasting demonstrated these long-term essential Importantly, induction T-cells,
increase XX, days induction the fold demonstrated first COVID-XX vaccination, without strong increase XX in a These XX PDSXXXX also to vaccine anti-SARS-CoV-X day by of within to a the immune. specific protein Specifically, over neutralizing SARS-CoV-X the when T-cells to Versamune. XX pre-clinical studies without compared XX XX confirmed fold antibodies of
to Importantly, comparable the antibodies observed XX levels these were day COVID-XX patients. hospitalized of neutralizing at in those
up levels induce demonstrate high pre-clinical vaccination. pre-clinical that PDSXXXX's these demonstrated against in Lastly, in ability XX protective further antibody rapidly hopeful virus-specific long-lasting pre-clinical data T-cells well antibodies substantial both increase days these a to levels humans. studies to results neutralizing to will after COVID-XX. the translate studies and showed These We're of
develop durable and breadth for safe a vaccine Our against goal vaccine the a provides next COVID-XX. with necessary immune and to is level generation that of protection effective responses
our are PDSXXXX a high and ability hand by by CFO, the responses. potential like We into responses into from NIAID. potential antiviral antibody a that its X for Michael currently killer this their pre-clinical into to clinical development the to The are are Phase other FDA complete interim human long-term Michael? investigating is feedback level of of trial development XXXX We our virus-specific advancing PDSXXXX vaccines these broad clinical range vaccine, committed our trials. program optimistic neutralize a hope progress recommendations flu to development clearly call protection to has We received differentiate Versamune to rapidly T-cell COVID-XX PDSXXXX plan from studies against quickly design a to being rapidly in pre-clinical both and We itself the ability by remain this virus. applied the being to studies the and on clinical Upcoming the now development I over from then killer confirm to King. PDSXXXX, studies. potential would to of trials induce to providing and recently funded additional PDSXXXX. working and also and universal grant pre-clinical immune induce incorporate immune in of responses
three financial I to the review months for results Thank our ended XX, June you, Lauren. would XXXX. like
same totaled period basic diluted Research compared a compared share of per quarter second of XXXX, quarter of XXXX, million was of decrease XXXX. in of the the the $X.X in million, second or a and or $X.XX net for to in approximately basic XX%. expenses development to XXXX, and approximately the million diluted $X.X approximately $X.X share, per loss loss For and second $X.X million, quarter $X.XX approximately net
for of expenses million, period second were approximately For total Total million, the $X.X for for compared of G&A approximately $X.X in the $X.X the approximately XX%. XX%. to a XXXX, the decrease expenses million a $X.X approximately operating were of quarter quarter compared operating with of XXXX, of quarter expenses decrease same million second XXXX, second
As $XX.X million. of June approximately the XX, Company's balance was cash
this announced of on underwriting six offering announced public are a consisting a week, Tuesday we at of expenses. previously million underwritten pricing common $XX.X addition, from In proceeds stock The offering, this expected per offering of $X.XX of be other public commissions, price to discounts, offering share. gross shares deducting million before and
In underwriting three to to underwriter, XX-day corporate granted remarks. intends data. PDSXXXX and at XXX,XXX Frank offering currently clinical Co., This capital use advance the to the with less trials to today, mentioned up fund would planned all shares as necessary conditions. clinical human discounts financial hand option and offering the the is X expected through resources general to expenses, for earlier, and back our Biotech financial addition, price, working call from to closing like final offering public the I subject customary to commissions. This Frank Phase common we've this provide we Frank? Because to concludes proceeds initial additional purchase Oppenheimer closing this statements. us will of a the stock
Thank you, Michael.
MD trial, team trial Phase validate in partnership and to past clinical Cancer Before in the initiation thank novel would partners and immuno-oncology. we the like our all the the at end over X platform their Anderson National Versamune Phase Cancer of with I field work dedicated of call, X upcoming quarter. our Institute, a Center to continue for clinical the The
In our Farmacore, pre-clinical COVID-XX of universal support trials. those and vaccine programs vaccine the advance human financial help recent will to the addition, NIAID the received the towards a has for of influenza the from partner, grant us development the development for clinical rapidly
coming of of and we forward metastatic HPV trial combination cancer. X Keytruda, or look positive head Over reinitiating recurrent and first line neck the our PDSXXXX to addressing Phase months, treatment
us the fund progress X advancing We of recent initial clinical development COVID-XX also Phase provides programs vaccine raise programs financial trials. our with look to The forward PDSXXXX to resources into through data. the our
XX months, to shareholders one also aim six milestones, their and disease on clinical multiple infectious thank remarks. Thank next aim products support. for pipeline work trial. continued the much our us progress deliver to you We prepared least joining our That of human to to at clinical concludes diligently today. our Over into very for we
conference. This concludes today's
your lines your this at for you participation. disconnect may time. Thank You